Obesity Medicine

Obesity physician-scientist Andres Acosta, MD, PhD, reviews findings from recent studies he led that suggest true potential for phenotype-focused weight loss intervention.

Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.

Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.

Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.

Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.

AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.

Semaglutide yields "amazing" weight loss in adolescents, phenotype-tailored lifestyle approach leads to greater weight loss vs standard methods, and more.

Weight management in children and adolescents with obesity requires unique sensitivity to the physical and emotional needs of these vulnerable pediatric patients.

AHA 2022: Study authors say more research is needed to investigate the impact of targeting social determinants of health to improve cardiometabolic risk and mortality in pregnant women.

The novel approach to targeted obesity treatment could improve weight loss outcomes, suggest findings from ObesityWeek® 2022.

Semaglutide 2.4 mg (Wegovy) weight loss benefits in adolescents mirror those seen in adults, according to phase 3a trial findings presented at ObesityWeek® 2022.

The American Gastroenterological Association released its first medical guideline recommending prescription medications for weight loss in adults with obesity. A review, here.

ObesityWeek 2022: Regardless of the number of obesity-related comorbidities, tirzepatide was associated with a greater reduction in body weight than placebo.

ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.

ObesityWeek 2022: Tirzepatide-induced weight reduction was associated with body composition improvements in adults with obesity/overweight, found analysis of SURMOUNT-1.

Adults with obesity who have an inadequate response to lifestyle interventions alone should be offered 1 of 4 suggested medications.

The first-in-class dual incretin receptor agonist was granted fast track designation for investigation in adults with obesity or overweight with weight-related comorbidities.

Children with obesity enrolled in the FitTastic study group had more favorable BMI patterns compared to control group, according to longitudinal effectiveness study.

Adolescents with severe obesity who underwent bariatric surgery before age 22 lost 31.1% body weight and kept it off over a decade later, showed new study.

Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

Educating patients with obesity about the link between poor sleep and weight gain is crucial. Review 5 key elements for achieving better sleep, here.

Phase II clinical trial shows a fixed dose combination of semaglutide/cagrilintide reduces HbA1c and weight much better than either drug alone.

A free, automated online behavioral weight loss program led to a mean 5% reduction in weight over 12 weeks without clinician involvement, a new study reports.

Excess weight diminishes the development and function of the musculoskeletal system at any point in the lifespan. An obesity specialist highlights the dangers.